Morgan Stanley Sees 2014 Guidance for Tenet Healthcare as Full of Puts and Takes


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


In a report published Tuesday, Morgan Stanley analyst Andrew Schenker reiterated an Equal-Weight rating on

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Tenet Healthcare (NYSE: THC).In the report, Morgan Stanley noted, “THC issued FY14 Adj. EBITDA guidance of $1.8B to $1.9B including reform benefit of $50M to $100M. Guidance compares with MS est. and consensus of $1.94B and 1.96B, respectively. THC's forecast assumes pro-forma admissions growth of -2% to flat adj. admissions growth of -1% to +1% and VHS synergies of $50M-$100M. Separately, the company anticipates 1Q14 adj. EBITDA of $350M-$400M including $10M in EHR, this compares with MS and street at $434M and $447M, respectively.”Tenet Healthcare closed on Monday at $48.33.
Posted In: Analyst ColorReiterationAnalyst RatingsAndrew SchenkerMorgan Stanley